Updates are available Correction dated 2025-05-28
Click to view Correction: https://doi.org/10.1038/s41746-025-01719-7
-
Authors
Ferle, Maximilian https://orcid.org/0000-0002-2730-4093
Grieb, Nora
Kreuz, Markus
Ader, Jonas
Goldschmidt, Hartmut
Mai, Elias K.
Bertsch, Uta
Platzbecker, Uwe
Neumuth, Thomas
Reiche, Kristin
Oeser, Alexander
Merz, Maximilian https://orcid.org/0000-0002-2805-5973
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 11 April 2025
First Online: 30 April 2025
Change Date: 28 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41746-025-01719-7
Competing interests
: H.G. received financial support from Janssen-Cilag GmbH, Celgene GmbH, Novartis Pharma GmbH, Onyx Pharmaceuticals Inc., Takeda Pharma Vertrieb GmbH and Roche Deutschland Holding GmbH. EKM received financial support from and had consultancy or advisory agreements with Amgen GmbH, Oncopeptides AB (publ), Bristol Myers Squibb/Celgene GmbH, GlaxoSmithKline GmbH, Janssen-Cilag GmbH, Pfizer Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Stemline Therapeutics, Inc., and Takeda Pharma Vertrieb GmbH. UP. received financial support from Syros Pharmaceuticals Inc., Silence Therapeutics GmbH, Celgene GmbH, Takeda Pharma Vertrieb GmbH, Fibrogen Inc., Servier Deutschland GmbH, Roche Deutschland Holding GmbH, Merck KGaA, Amgen Inc., Novartis Pharma GmbH, Curis Inc., Janssen Pharmaceuticals Inc., Jazz Pharmaceuticals Inc., BeiGene Germany GmbH, Geron Inc., and Bristol-Myers Squibb GmbH. A.O. received financial support from Janssen-Cilag GmbH. MM received financial support from SpringWorks Therapeutics Inc., Janssen-Cilag GmbH, and Roche Deutschland Holding GmbH. M.F., N.G., M.K., J.A., U.B., T.N., and K.R. declare no competing interests.
